Marburg Virus Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major marburg virus disease markets are expected to exhibit a CAGR of 5.5% during 2024-2034.
The Marburg virus disease market has been comprehensively analyzed in IMARC's new report titled "Marburg Virus Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Marburg virus disease (MVD) refers to a rare but severe viral illness caused by the Marburg virus, a member of the Filoviridae family. The virus is originally derived from animal hosts like bats and can be transmitted to humans through direct contact with bodily fluids or tissues from infected animals or humans. The symptoms of the ailment typically begin abruptly with fever, chills, headaches, and muscle aches. As the illness progresses, individuals suffering from MVD may also experience severe gastrointestinal signs like vomiting, diarrhea, and abdominal pain. A characteristic manifestation is the development of a maculopapular rash and inflammation of the conjunctiva. The disease can swiftly escalate to severe hemorrhaging, organ failure, and shock, leading to a high fatality rate. Diagnosing MVD is challenging due to its similarity to various other infectious diseases in the early stages. Early detection relies on a combination of clinical evaluation and laboratory tests to detect the virus's genetic material and identify specific antibodies.
The escalating cases of viral disorders that can spread to humans through direct contact with the bodily fluids of infected animals are primarily driving the Marburg virus disease market. Furthermore, the increasing prevalence of somatic mutations in specific genes, leading to the hyperactivation of certain cellular pathways and triggering a cascade of detrimental effects on the immune and vascular systems, is also propelling the market growth. In addition to this, the inflating utilization of antiviral treatments like favipiravir, ribavirin, and monoclonal antibodies to manage the condition is creating a positive outlook for the market. Moreover, the widespread adoption of stringent infection prevention and control measures in healthcare settings and communities, owing to the extremely contagious nature of the virus, is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic tools, such as reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), which are crucial for early detection and timely medical intervention, is acting as another significant growth-inducing factor. Additionally, the increasing investments in the development of vaccines, with a focus on utilizing vector-based or subunit approaches to prevent the spread of the condition, are expected to drive the Marburg virus disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Marburg virus disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Marburg virus disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Marburg virus disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Marburg virus disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Marburg virus disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Marburg virus disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the Marburg virus disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Marburg virus disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Marburg virus disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Marburg virus disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Marburg virus disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Marburg virus disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Marburg virus disease across the seven major markets?
What is the size of the Marburg virus disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Marburg virus disease?
What will be the growth rate of patients across the seven major markets?
Marburg Virus Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Marburg virus disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Marburg virus disease market?
What are the key regulatory events related to the Marburg virus disease market?
What is the structure of clinical trial landscape by status related to the Marburg virus disease market?
What is the structure of clinical trial landscape by phase related to the Marburg virus disease market?
What is the structure of clinical trial landscape by route of administration related to the Marburg virus disease market?
The Marburg virus disease market has been comprehensively analyzed in IMARC's new report titled "Marburg Virus Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Marburg virus disease (MVD) refers to a rare but severe viral illness caused by the Marburg virus, a member of the Filoviridae family. The virus is originally derived from animal hosts like bats and can be transmitted to humans through direct contact with bodily fluids or tissues from infected animals or humans. The symptoms of the ailment typically begin abruptly with fever, chills, headaches, and muscle aches. As the illness progresses, individuals suffering from MVD may also experience severe gastrointestinal signs like vomiting, diarrhea, and abdominal pain. A characteristic manifestation is the development of a maculopapular rash and inflammation of the conjunctiva. The disease can swiftly escalate to severe hemorrhaging, organ failure, and shock, leading to a high fatality rate. Diagnosing MVD is challenging due to its similarity to various other infectious diseases in the early stages. Early detection relies on a combination of clinical evaluation and laboratory tests to detect the virus's genetic material and identify specific antibodies.
The escalating cases of viral disorders that can spread to humans through direct contact with the bodily fluids of infected animals are primarily driving the Marburg virus disease market. Furthermore, the increasing prevalence of somatic mutations in specific genes, leading to the hyperactivation of certain cellular pathways and triggering a cascade of detrimental effects on the immune and vascular systems, is also propelling the market growth. In addition to this, the inflating utilization of antiviral treatments like favipiravir, ribavirin, and monoclonal antibodies to manage the condition is creating a positive outlook for the market. Moreover, the widespread adoption of stringent infection prevention and control measures in healthcare settings and communities, owing to the extremely contagious nature of the virus, is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic tools, such as reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), which are crucial for early detection and timely medical intervention, is acting as another significant growth-inducing factor. Additionally, the increasing investments in the development of vaccines, with a focus on utilizing vector-based or subunit approaches to prevent the spread of the condition, are expected to drive the Marburg virus disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Marburg virus disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Marburg virus disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Marburg virus disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Marburg virus disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Marburg virus disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Marburg virus disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report:
Market Insights
How has the Marburg virus disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Marburg virus disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Marburg virus disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Marburg virus disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Marburg virus disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Marburg virus disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Marburg virus disease across the seven major markets?
What is the size of the Marburg virus disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Marburg virus disease?
What will be the growth rate of patients across the seven major markets?
Marburg Virus Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Marburg virus disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Marburg virus disease market?
What are the key regulatory events related to the Marburg virus disease market?
What is the structure of clinical trial landscape by status related to the Marburg virus disease market?
What is the structure of clinical trial landscape by phase related to the Marburg virus disease market?
What is the structure of clinical trial landscape by route of administration related to the Marburg virus disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MARBURG VIRUS DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MARBURG VIRUS DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MARBURG VIRUS DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MARBURG VIRUS DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MARBURG VIRUS DISEASE - UNMET NEEDS
10 MARBURG VIRUS DISEASE - KEY ENDPOINTS OF TREATMENT
11 MARBURG VIRUS DISEASE - MARKETED PRODUCTS
11.1 List of Marburg Virus Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MARBURG VIRUS DISEASE - PIPELINE DRUGS
12.1 List of Marburg Virus Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 cAd3-Marburg - Sabin Vaccine Institute
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MARBURG VIRUS DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MARBURG VIRUS DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MARBURG VIRUS DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Marburg Virus Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Marburg Virus Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Marburg Virus Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Marburg Virus Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Marburg Virus Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Marburg Virus Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Marburg Virus Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Marburg Virus Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Marburg Virus Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Marburg Virus Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Marburg Virus Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Marburg Virus Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Marburg Virus Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Marburg Virus Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Marburg Virus Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Marburg Virus Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Marburg Virus Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Marburg Virus Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Marburg Virus Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Marburg Virus Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Marburg Virus Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Marburg Virus Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Marburg Virus Disease - Access and Reimbursement Overview
16 MARBURG VIRUS DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MARBURG VIRUS DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MARBURG VIRUS DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MARBURG VIRUS DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MARBURG VIRUS DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MARBURG VIRUS DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MARBURG VIRUS DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MARBURG VIRUS DISEASE - UNMET NEEDS
10 MARBURG VIRUS DISEASE - KEY ENDPOINTS OF TREATMENT
11 MARBURG VIRUS DISEASE - MARKETED PRODUCTS
11.1 List of Marburg Virus Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MARBURG VIRUS DISEASE - PIPELINE DRUGS
12.1 List of Marburg Virus Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 cAd3-Marburg - Sabin Vaccine Institute
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MARBURG VIRUS DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MARBURG VIRUS DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MARBURG VIRUS DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Marburg Virus Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Marburg Virus Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Marburg Virus Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Marburg Virus Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Marburg Virus Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Marburg Virus Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Marburg Virus Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Marburg Virus Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Marburg Virus Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Marburg Virus Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Marburg Virus Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Marburg Virus Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Marburg Virus Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Marburg Virus Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Marburg Virus Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Marburg Virus Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Marburg Virus Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Marburg Virus Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Marburg Virus Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Marburg Virus Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Marburg Virus Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Marburg Virus Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Marburg Virus Disease - Access and Reimbursement Overview
16 MARBURG VIRUS DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MARBURG VIRUS DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MARBURG VIRUS DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
